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Background: The emergence of transmitted drug resistance (TDR) compromises the effect of antiretroviral therapy
(ART), resulting in treatment failure of human immunodeficiency virus (HIV) disease. Although more than a decade
has passed since ART was introduced into Indonesia, information on TDR is limited. Here, a genotypic study of TDR
among ART-naïve individuals was conducted in Surabaya, Indonesia.
Method: HIV-1 seropositive participants were recruited from the communities of commercial sex workers and
intravenous drug users as well as from the university teaching hospital in Surabaya. Protease (PR) and reverse
transcriptase (RT) genes were sequenced in order to conduct HIV-1 subtyping and phylogenetic analysis and to
detect TDR. TDR was defined as the presence of at least one surveillance drug resistance mutation on the WHO list
or major drug resistance mutations in the International AIDS Society-USA panel.
Result: Fifty two and 47 of the PR and RT genes, respectively, were successfully sequenced in the 58 samples. HIV-1
subtyping revealed that 86.3% (50/58) of the sequenced samples were classified as CRF01_AE, 8.6% as subtype B,
3.4% as B/CRF01_AE, and 1.7% as A/G/CRF01_AE. TDR of PR inhibitors was not detected in this study. In contrast,
TDR of RT inhibitors was detected in 4.3% (2/47) of samples. In addition, minor drug resistance mutations were
detected in 98.1% (51/52) and 12.8% (6/47) of PR and RT genes, respectively.
Conclusion: This study clarified the predominance of the CRF01_AE strain in Surabaya, Indonesia. The prevalence of
TDR was below 5%, indicating that the currently available first-line regimen is still effective in Surabaya. However,
the prevalence might be underestimated since we detected only major population of HIV-1 in individuals.
Therefore, continuous surveillance is required in order to detect the emergence of TDR in the early phase.
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Antiretroviral therapy (ART) achieved the reduction of
viral transmission, morbidity and mortality associated with
human immunodeficiency virus (HIV) disease. However,
the emergence of transmitted drug resistance (TDR) as a
consequence of ART expansion represents a serious pub-
lic health problem because TDR affects the treatment* Correspondence: mkameoka@port.kobe-u.ac.jp
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unless otherwise stated.efficacy and clinical outcome [1,2]. Although the preva-
lence of TDR in resource-limited countries is currently
<5% [3], it is expected to increase with ART expansion.
TDR is a permanent challenge for HIV disease control.
HIV-1 is subdivided into four groups, M (major), O
(outlying), N (new or non-M, non-O), and P. Group M
accounts for the majority of HIV-1 infections. The
viruses in group M are further classified into subtypes,
circulating recombinant forms (CRFs) and unique re-
combinant forms (URFs), which are prevalent in specific
geographic regions. While subtype B of HIV-1 is the pre-
dominant subtype in the Americas, Europe, and Australia,This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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in Africa and Asia [4]. CRF01_AE is the major CRF preva-
lent throughout Southeast Asian countries including
Indonesia [4]. Although surveillance studies on TDR have
been conducted in Southeast Asian countries where
CRF01_AE is prevalent, information on TDR as well as on
CRF01_AE viruses is still limited [3,5].
In Indonesia, the estimated number of people living
with HIV has been increasing and reached 610,000 in
2012, even though that of other Southeast Asian countries
is stable or in decline [6]. Accordingly, it was estimated
that the number of people eligible for ART, whose CD4+
T-cell count was below 500 cells/mm3 (WHO criteria),
would reach 510,000 in 2013 [6]. Even though the
Indonesian government launched an ART expansion
program in 2004 [7], the coverage rate among patients
in need of ART was less than 18% until 2010 [6]. How-
ever, it increased markedly to 40% in 2011 according to
the Ministry of Health, Mathematic Model of HIV Epi-
demic in Indonesia [8]. The number of patients with
access to ART is therefore increasing in Indonesia.
The first-line regimen of ART recommended in
Indonesia is a combination of two nucleoside reverse-
transcriptase inhibitors (NRTIs) and a non-nucleoside
reverse-transcriptase inhibitor (NNRTI) [5]. Lamivudine
(3TC), zidovudine (AZT), tenofovir (TDF), nevirapine
(NVP) and efavirenz (EFV) are commonly used. For pa-
tients with virological failure or adverse effects, ritonavir-
boosted protease inhibitors (PIs) in combination with two
NRTIs are recommended as the second-line regimen [5].
Other drugs, including didanosine (ddI), etravirine (ETR)
and rilpivirine (RPV), are uncommon in Indonesia.
Although ART is successful in Indonesia, the emergence
of drug resistance has been reported among treatment-
failure patients [9]. After a decade of ART expansion in
Indonesia, the emergence of TDR is inevitable. However,
there are limited data on TDR among ART-naïve patients
in Indonesia. It is important to monitor the prevalence of
TDR in countries where the drug options are limited. In
this report, a genotypic study of TDR among ART-naïve
patients was conducted in Surabaya, Indonesia.
Results
Demographic data of the study subjects
Peripheral blood samples were collected from the partici-
pants from the communities of commercial sex workers
(CSWs) and intravenous drug users (IDUs) as well as from
the university teaching hospital in Surabaya. All partici-
pants were confirmed to be ART naïve at interview and/or
from medical records. RNA and DNA were extracted from
plasma and peripheral blood mononuclear cells (PBMC),
respectively, isolated from peripheral blood samples. If a
viral gene fragment failed to be amplified from the cDNA
even after multiple attempts, it was amplified instead fromDNA. In order to examine the genomic fragment of the
major viral population in a sample, PCR products ampli-
fied at the end-point dilution of DNA templates were sub-
jected to sequencing analysis.
As a result, 52 and 47 of the protease (PR) and reverse
transcriptase (RT) genes, respectively, were successfully
sequenced in the 58 samples. Of these, 13 and 22 of the
PR and RT genes, respectively, were derived from DNA.
The demographic data of the 58 individuals are shown
in Table 1, along with the results of viral subtyping
described below. Mean age was 33.2 years old (range
17–51). There was no significant difference in age and
subtype among study participants. Detailed patient infor-
mation including age, sample collection date and trans-
mission route is shown in Additional file 1.
HIV-1 subtyping and phylogenetic analysis
HIV-1 subtyping was carried out for PR and RT gene
sequences separately using recombinant identification
program (RIP). Most PR and RT gene sequences were
classified as CRF01_AE or subtype B. However, two RT
gene sequences derived from SM11 and IDU11 were
classified as B/CRF01_AE, and PR and RT gene sequences
derived from PJ121 were G/CRF01_AE and A/G/
CRF01_AE, respectively (Additional file 1). Phylogen-
etic trees of PR and RT gene sequences are shown in
Figure 1. HIV-1 subtyping by phylogenetic analysis was
consistent with RIP results, except for PJ121. With re-
gard to the samples from PJ121, for the PR gene,
phylogenetic analysis showed that it was clustered with
subtype G and CRF02_AG, while RIP showed that it
was G/CRF01_AE. For the RT gene, phylogenetic ana-
lysis showed its relevance to CRF01_AE, whereas RIP
showed that it was A/G/CRF01_AE. Taken together, 50
samples (86.3%) were classified as CRF01_AE, 5 samples
(8.6%) as subtype B, 2 samples (3.4%) as B/CRF01_AE and
a sample (1.7%) derived from PJ121 as A/G/CRF01.
In addition, jumping profile Hidden Markov Models
(jpHMM) analysis revealed that viral gene fragments
derived from SM11 and IDU11 (B/CRF01_AE) had their
breakpoints at 2884–2883 and 2889–2909 (HXB2
position), respectively, which were similar to that of
CRF33_01B reference strains (2847–2884) (Additional
file 2). The breakpoint of the viral gene fragment from
PJ121 was not similar to that of the CRFs registered in
the Los Alamos HIV sequence database (http://
www.hiv.lanl.gov/content/sequence/HIV/CRFs/
CRFs.html).
Genotypic analysis of drug resistance for PR gene
In this study, TDR was defined as the presence of at
least one major drug resistance mutation listed in the
international AIDS Society (IAS)-USA panel or surveillance
drug resistance mutation in world health organization
Table 1 Demographic characteristics, viral subtypes and time after infection of study subjects*
All (n = 58) CSW community (n = 22) IDU community (n = 16) Hospital (n = 20)
Mean age (years old) 32.2 30.3 33.9 33.0
Gender
Male 26 (44.8%)** 0 (0%) 15 (93.8%) 11 (55.0%)
Female 32 (55.2%) 22 (100%) 1 (6.2%) 9 (45.0%)
Viral subtype
CRF01_AE 50 (86.3%) 20 (91.0%) 12 (75.0%) 18 (90.0%)
Subtype B 5 (8.6%) 0 (0%) 3 (18.8%) 2 (10.0%)
B/CRF01_AE recombinant 2 (3.4%) 1 (4.5%) 1 (6.2%) 0 (0%)
A/G/CRF01_AE recombinant 1 (1.7%) 1 (4.5%) 0 (0%) 0 (0%)
*There was no significant difference among study participants from the communities of CSWs and IDUs, and from Airlangga University Teaching Hospital in terms
of mean age and viral subtype. Gender was statistically different because we aimed to recruit female CSW.
**The proportion (%) of the number of individuals in a question item is shown in parentheses.
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TDR was not detected in PR gene sequences. However,
minor drug resistance mutations listed in the IAS-USA
panel were detected in 98.1% (51/52) of the study subjects,
shown in Table 2 [10]: L10I/V, G16E, K20R, L33F, M36I/L,
I62V, L63P, I64V, H69K/R, V77I, V82I, L89M/I and I93L.
Each CRF01_AE strain possessed at least 3 and up to 8
mutations. M36I/L, H69K/R and L89M/I were highly
conserved in the CRF01_AE strain, at rates of 95.7%
(45/47), 100% and 100%, respectively (Table 2). These
mutations were known as natural polymorphism among
CRF01_AE [12].
Genotypic analysis of drug resistance for RT gene
Two of 47 samples (4.3%) possessed TDR in RT gene
sequences. The RT gene fragment from SM18 contained
a K101E mutation, which is a major drug resistance mu-
tation to NNRTI; ETR and RPV [10]. Interestingly, the
sample from UA6 contained 6 major drug resistance
mutations: D67N, K70R, M184V, T215F, K219Q, confer-
ring resistant to almost all NRTI (except ddI), and
K103N conferring resistance to NNRTI; NVP and EFV
[10]. RT gene fragment of UA6 was amplified from un-
diluted DNA (because of the failure of PCR from diluted
DNA), indicating that minor population of HIV also pos-
sessed multiple TDR. The failure of PCR using RNA
might be due to poor sample storage condition. Other
than TDR, four minor drug resistance mutations (A98G,
E138G/A, V179D), which confer resistance to ETR and/
or RPV, were detected among 6 samples of CRF01_AE
(12.8%: 6/47) [10]. The data are summarized in Table 3.
Discussion
Here we report the circulating HIV-1 subtype and the
prevalence of TDR among 58 HIV-1-infected drug-naïve
individuals in Surabaya, Indonesia. Of 58 sequenced
samples, 50 (86.3%) were classified as CRF01_AE, 5
(8.6%) as subtype B, 2 (3.4%) as B/CRF01_AE, and 1(1.7%) as A/G/CRF01_AE. These results are consistent
with a previous report on the predominance of CRF01_AE
in Southeast Asian countries [4]. According to the
phylogenetic tree of RT gene and jpHMM analysis, B/
CRF01_AE recombinants in Surabaya were closely re-
lated to CRF33_01B, which was currently reported in
Indonesia [13]. The viral gene derived from PJ121, an
A/G/CRF01_AE recombinant, seems a URF because its
breakpoint and recombination pattern had not been
reported as of December 2014, in the Los Alamos HIV
sequence database. The HIV gene fragment analyzed in
the present study was not informative enough to deter-
mine actual CRFs. Further sequence analysis of different
regions must therefore be carried out.
Genotypic analysis of drug resistance revealed no evi-
dence of the circulation of TDR against PIs in Surabaya.
This was not surprising because access to PIs is limited
in Surabaya, even though PI is recommended as the
second-line regimen. Interestingly, each CRF01_AE strain
possessed 3 to 8 minor drug resistance mutations based
on the IAS-USA panel [10]. Although these mutations
were considered natural polymorphisms of CRF01_AE,
the accumulation of minor mutations may affect the effi-
cacy of PIs. Further studies are necessary to clarify their
impact on the susceptibility of PIs.
In contrast, the prevalence of TDR against RT inhibi-
tors was 4.3% (2/47). This was consistent with a previous
report that TDR in Asian countries was <5%, but is
gradually increasing [3]. The sample from SM18 con-
tained a K101E mutation conferring resistance to ETR
and RPV [10]. However, the emergence of K101E is
probably not associated with ART expansion in Indonesia
because ETR and RPV are not commonly used. It is con-
sidered that K101E appeared as a natural polymorphism
in Indonesian CRF01_AE. In contrast, the RT gene frag-
ment derived from UA6 possessed 6 major mutations and
1 minor mutation. The virus in UA6 is considered to be
resistant to the common first-line regimen in Indonesia
Figure 1 Neighbor-joining phylogenetic trees of PR and RT gene sequences. Phylogenetic trees were constructed for newly sequenced
HIV-1 PR (A) and RT (B) genes along with the corresponding viral gene of reference HIV-1 strains, representing subtype A1, subtype A2, subtype
B, subtype C, subtype D, subtype G, CRF01_AE, CRF02_AG, CRF15_01B and CRF33_01B. The reference strains of the HIV-1 subtype were shown in
blue and bold. The sequence codes are presented as the GenBank accession number, patient ID or name of reference strain, and the subtype or
CRF of reference strain (shown in parentheses) in order. DNA or RNA following the patient ID indicates the origin of the viral sequence, i.e., DNA
extracted from PBMC or RNA extracted from a plasma sample, respectively. Bootstrap values are shown when the values are >70.
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probably infected with HIV-1 by heterosexual intercourse
(Additional file 1), indicating that the HIV-1 with multiple
TDR had enough growth fitness for sexual transmission.
A multiple drug resistant HIV was confirmed among
drug-naïve HIV patient in Surabaya.
Four minor mutations (A98G, E138G/A, V179D)
conferring resistance to ETR and/or RPV were detected
among 6 samples. However, they are considered naturalpolymorphisms because these mutations are excluded
from the WHO list [11], and ETR and RPV are not com-
monly used in Indonesia.
In the WHO TDR surveillance guideline, the preva-
lence of TDR is categorized into three groups: <5% (low
level), 5–15% (medium level) and >15% (high level)
[14,15]. The <5% level is the desired threshold for any
country scaling up ART. According to this guideline, the
currently recommended first- and second-line regimens
Table 2 Appearance of minor drug resistance mutations
in PR gene*
Mutation Frequency (%)






L10I/V 11 (21.2) 10 (21.3) 1 (25.0) 0 (0)
G16E 16 (30.8) 15 (31.9) 1 (25.0) 0 (0)
K20R 19 (36.5) 19 (40.4) 0 (0) 0 (0)
L33F 7 (13.5) 7 (14.9) 0 (0) 0 (0)
M36I/L 46 (88.5) 45 (95.7) 0 (0) 1 (100)
I62V 6 (11.5) 6 (12.8) 0 (0) 0 (0)
L63P 5 (9.6) 4 (8.5) 0 (0) 1 (100)
I64V 3 (5.8) 2 (4.3) 1 (25.0) 0 (0)
H69K/R 48 (92.3) 47 (100) 0 (0) 1 (100)
V77I 12 (23.1) 10 (21.3) 2 (50.0) 0 (0)
V82I 3 (5.8) 3 (6.4) 0 (0) 0 (0)
L89M/I 48 (92.3) 47 (100) 0 (0) 1 (100)
I93L 15 (28.8) 12 (25.5) 3 (75.0) 0 (0)
*Mutations were detected manually according to the International AIDS
Society-USA panel.
Kotaki et al. AIDS Research and Therapy  (2015) 12:5 Page 5 of 7are appropriate in Surabaya, Indonesia. However, there
were several limitations in the design of this study. Our
sample collection might have been biased because partici-
pants were recruited from CSW and IDU communities. In
addition, although the WHO guidelines aimed to recruit
recently infected individuals (below 25 years of age, CD4+
T-cell counts above 500 cells/mm3) [15], these were not
used in this study for practical reasons. A previous report
indicated that certain drug resistance mutations would re-
vert to the wild type in the absence of selective pressure
by ART [16]. Therefore, it is probable that our data may
underestimate the prevalence of TDR. However, the TDR
including most thymidine analogue mutations (M41L,
D67N, K70R, L210W, T215 revertant but not T215Y/F
and K219Q) and K103N, which were stable in the absence
of ART, were rarely detected in our study subjectsTable 3 Demographic characteristics of 6 individuals infected w
ID Group Subtype Drug resistanc
NNRTI
SM18 CSW CRF01_AE K101E**E138G
UA6 Hospital CRF01_AE K103N A98G
IDU9 IDU CRF01_AE E138A
UA7 Hospital CRF01_AE E138A
UA15 Hospital CRF01_AE V179D
DN6 Hospital CRF01_AE E138G
*HIV-1 drug resistance mutations were detected according to the International AIDS
**Major drug resistance mutations are shown in bold.
***Highly resistant drugs are shown in bold.even though they have been frequently detected among
treatment-failure patients in Indonesia [9,16]. Therefore, it
was estimated that the prevalence of TDR among the
population recently infected with HIV-1 is not high. It is
helpful for the future ART strategy to clarify the preva-
lence of TDR among patients who are about to start ART,
even if the study subjects are biased and may not reflect
recent infections. Other than the quality of samples, direct
sequencing might cause underestimation, as previously re-
ported [17,18]. Considering these limitations, the data
must be evaluated carefully.
Conclusion
The prevalence of TDR among ART-naïve patients in
Surabaya was <5%, which is categorized as low by WHO.
However, additional or continuous surveillance must be
conducted because this study had several limitations, and
the prevalence might be underestimated and biased. The
low TDR observed in this study calls for continuous mon-
itoring of TDR in order to detect the emergence of TDR
in the early phase.
Materials and methods
Ethics statement
This study was conducted with approval from the ethics
committee of the Airlangga University (permission number:
25-995/UN3.14/PPd/2013) and the medical ethics com-
mittee at Kobe University Graduate School of Medicine
(permission number: 784), and written informed consent
was obtained from study participants.
Participant recruitment and sample collection
Participants were recruited from the communities of
CSWs and IDUs as well as from the university teaching
hospital in Surabaya. The CSW study subjects were the
same as in a previous report [19]. All participants were
confirmed to be ART naïve at interview and/or from
medical records. Samples were collected between October
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Society-USA panel and WHO surveillance list.
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eral blood was collected from each participant. Plasma
was then isolated from peripheral blood samples. In
addition, peripheral blood mononuclear cells (PBMC)
were isolated by density gradient centrifugation using
Histopaque 1077 (Sigma-Aldrich, St. Louis, MO, USA).
RNA and DNA were extracted from plasma and PBMC
using the QIAamp Viral RNA Mini kit (Qiagen, Hil-
den, Germany) and the GenElute Mammalian Gen-
omic DNA Miniprep kit (Sigma-Aldrich),
respectively.
Amplification of HIV-1 genomic fragment and sequence
analysis
Viral RNA was reverse transcribed to cDNA using the
SuperScript III First-Stand Synthesis kit (Invitrogen,
Carlsbad, CA, USA). Generated cDNA was subjected
to amplification of the viral gene for both the PR and
RT encoding regions in a separate reaction by nested
PCR using Ex Taq (Takara Bio, Shiga, Japan). Primer
information is shown in Additional file 3. If a viral gene
fragment failed to be amplified from the cDNA even
after multiple attempts, it was amplified instead from
DNA extracted from PBMC. In order to examine the
genomic fragment of the major viral population in a
sample, PCR products amplified at the end-point dilu-
tion of DNA templates were subjected to sequencing
analysis.
Sequencing analysis of the amplified fragment was per-
formed using the BigDye Terminator v3.1 Cycle Sequen-
cing kit with an ABI PRISM 3500 × l genetic analyzer
(Applied Biosystems, Foster City, CA, USA). Data were
assembled and aligned using Genetyx ver. 10 software
(Genetyx, Tokyo, Japan). Nearly the full length of the PR
gene [(280 bp; corresponding to nucleotides 2262 to
2541 of a HIV-1 reference strain, HXB2 (GenBank ac-
cession no. K03455)] and part of the RT gene (762 bp;
nucleotides 2550 to 3311) were sequenced and subjected
to subsequent analysis.
HIV-1 subtyping and phylogenetic analysis
Obtained sequence data were subjected to HIV-1 sub-
typing using the RIP, available at the website of the
HIV sequence database (www.hiv.lanl.gov/). In addition,
neighbor-joining (NJ) trees with a Kimura two-parameter
model were constructed using MEGA5.2 software
[20–22]. Bootstrap values (1,000 replicates) for relevant
nodes were reported on a representative tree [23]. If
one of the PR and RT genes are failed to be se-
quenced, the subtype was assigned based on the other
gene. In addition, breakpoints of the recombinant
forms were determined by using the jpHMM (http://
jphmm.gobics.de/) [24]. The nucleotide sequences of
these PR and RT genes have been deposited in theGenBank database under accession numbers KJ865301-
KJ865352 and KJ865353-KJ865399.
Detection of drug resistance mutations
HIV-1 TDRs were detected manually according to the
IAS-USA panel and WHO surveillance list [10,11]. In
this study, TDR in a patient was defined as the presence
of at least one major drug resistance mutation listed in
the IAS-USA panel or surveillance drug resistance muta-
tion in WHO surveillance list. In addition to TDR, minor
drug resistance mutations in the IAS-USA panel were de-
tected as well [10].
Statistical analysis
Statistical analysis was performed using Fisher’s exact
test for categorical variables. The P value was calculated
using the program available at the web site, http://aoki2.-
si.gunma-u.ac.jp/exact/fisher/getpar.html. P values ≤0.05
were considered to be significant.
Additional files
Additional file 1: Detailed patient information of each participant.
Additional file 2: Subtyping analysis of the recombinant HIV-1
strains using jpHMM A-C). jpHMM results of SM11, PJ121 and IDU11.
Numbers in this figure are based on HXB2 numbering. Posterior
probability values are indicated on the y axis and nucleotide positions
based on the HXB2 sequence are shown on the x axis.
Additional file 3: Primer information.
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